Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Aug 03, 2026
KLA Corporation (KLAC) Shares Drop -25% in 30 Days: Semiconductor Sector Rotation at Work

KLA Corporation (KLAC) Shares Drop -25% in 30 Days: Semiconductor Sector Rotation at Work

Key Takeaways

  • KLA Corporation (KLAC) shares have fallen approximately 25% over the past 30 days, plunging from $235.55 on July 2 to $176.30 as of early August 2026.
  • The decline is part of a broader semiconductor sector rotation, with the stock down roughly 42% from its June 30 all-time high of $301.71.
  • Insider selling by senior executives, combined with growing fears of a slowdown in AI-related capital spending, accelerated the sell-off.
  • Despite the sharp pullback, KLA reported strong Q3 fiscal 2026 results in April and maintained a four-quarter earnings beat streak heading into its July 28 Q4 report.
  • Over the full quarter, KLAC is essentially flat — rising from approximately $173 in early May to the June 30 peak before giving back all gains — reflecting extreme volatility rather than a sustained downtrend.

KLA Corporation (KLAC) Company Overview and Market Position

KLA Corporation is a global leader in semiconductor process control and yield management solutions. The company designs, manufactures, and markets inspection and metrology equipment, software, and services used by chipmakers to detect defects, measure critical dimensions, and improve manufacturing yield across wafer fabrication, photomask, and advanced packaging operations. KLA holds dominant market share — approximately 50% to 60% in wafer inspection and 40% to 50% in metrology equipment — and counts industry giants such as TSMC, Samsung, and Intel among its key customers. With a market capitalization that exceeded $280 billion at its peak, KLA is one of the largest semiconductor equipment companies in the world and a bellwether for capital spending trends across the chip industry.

KLA Corporation (KLAC) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, KLAC shares have experienced a sharp decline of approximately 25%, dropping from a closing price of $235.55 on July 2 to $176.30 by early August. The sell-off was particularly acute in the final week of July, when the stock fell from $203.36 on July 27 to an intraday low near $170 on July 29 — a two-day plunge exceeding 16% — coinciding with the company's fiscal Q4 2026 earnings release on July 28.

Zooming out to the full quarterly picture reveals a dramatically different narrative. In early May 2026, KLAC traded near $173. The stock then staged an extraordinary rally, surging to an all-time high of $301.71 on June 30 — a gain of roughly 74% in under two months — fueled by aggressive analyst price target increases, a 10-for-1 stock split on June 12, and euphoria around AI-driven semiconductor demand. Since that peak, however, the stock has surrendered all those gains, returning to nearly the same level where the quarter began. The result is a quarter that appears flat on paper but masks one of the most volatile periods in the company's history. I also checked this using Tickeron’s AI Pattern Search Engine to see how the price action compared to historical patterns in the sector.

What Drove KLAC Stock Price in the Last 30 Days

Several interconnected factors drove KLAC's 25% decline over the past month. First, a broad-based rotation out of high-valuation semiconductor and AI-linked names accelerated in early July. As detailed by MarketBeat, KLAC suffered a "steep valuation-driven decline" amid mounting concerns that chipmakers may curb AI-related capital expenditures after years of aggressive spending. With a forward P/E ratio exceeding 55x at the peak, the stock was particularly vulnerable to any shift in sentiment.

Second, insider selling added pressure. SEC filings revealed that CFO Bren D. Higgins sold 27,701 shares at an average price of $265.69 on July 2, while EVP Mary Beth Wilkinson sold 14,392 shares at $285.30 on July 1 — collectively totaling over $11 million. Although Wilkinson's sale was attributed to tax withholding obligations, the transactions coincided with the stock's peak and amplified bearish sentiment.

Third, analyst caution grew. On July 20, UBS maintained a Neutral rating while lowering its price target from $255 to $240. The July 28 earnings report became a pivotal event; despite KLA's strong fundamentals, the market had priced in an aggressive growth narrative, and any sign of moderation in forward guidance risked triggering further selling.

Finally, macroeconomic uncertainty — including tariff-related cost pressures and gross margin headwinds from elevated DRAM component costs cited by management — contributed to the risk-off posture among institutional investors.

What Drove KLAC Stock Performance Over the Last Quarter

The quarterly story for KLAC is one of two distinct halves. From early May through late June, the stock rode a wave of optimism driven by a series of bullish analyst actions: Cantor Fitzgerald raised its price target to $325, TD Cowen lifted its target to $260, and Morgan Stanley boosted its target to $274 — all citing strong AI-linked demand for process control equipment and advanced packaging. The company's 10-for-1 stock split on June 12 further amplified retail and institutional buying interest, propelling shares to record levels.

The company's fundamental performance supported the rally. KLA's Q3 fiscal 2026 results, reported April 29, delivered non-GAAP diluted EPS of $9.40 on revenue of $3.42 billion, both exceeding consensus estimates. Management raised its long-term revenue CAGR target to 13%–17% through 2030 and highlighted advanced packaging process-control revenue growth of approximately 57% year-over-year. However, the same quarter also revealed early signs of gross margin pressure from DRAM-related costs and tariffs — issues that would later weigh on investor sentiment as the AI spending narrative began to crack in July. The quarter ultimately became a textbook case of how valuation compression can erase fundamental gains when market sentiment pivots.

KLAC Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several key factors will determine KLAC's trajectory. The July 28 fiscal Q4 2026 earnings report and management's forward guidance — particularly around semiconductor process-control systems revenue growth and the 2027 outlook — will be critical in either stabilizing or further pressuring the stock. Investors should closely monitor capital expenditure trends among major chipmakers, especially TSMC and Intel, as any softening in fab equipment spending directly impacts KLA's order pipeline. The memory market recovery trajectory and advanced packaging demand — where KLA has aggressively grown market share — remain important catalysts. Macroeconomic variables including tariff policy, interest rate expectations, and global semiconductor trade dynamics also warrant close attention. While KLA's dominant market position, strong free cash flow generation, and 87% institutional ownership provide a solid foundation, the stock's ability to regain upward momentum will largely depend on whether the AI capital spending narrative regains credibility in the months ahead. One thing that stands out from reviewing the data is how sensitive the name remains to shifts in AI spending expectations.

Using AI-Powered Trading Tools in Volatile Markets

In volatile market environments like the one currently affecting semiconductor stocks, I often turn to automated strategies to help navigate rapid price swings. Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots, drawn from a pool of hundreds of bots actively trading thousands of tickers across equities, ETFs, and forex. Only the top-performing and most relevant bots are featured, each with distinct strategies, timeframes, and performance metrics tailored to different market conditions. Exploring this resource has helped me identify approaches that complement my own research when sector rotation creates sharp moves like the one we saw in KLAC.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: KLAC

KLAC's RSI Oscillator recovers from oversold territory

The RSI Oscillator for KLAC moved out of oversold territory on July 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 11 similar instances when the indicator left oversold territory. In of the 11 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where KLAC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KLAC advanced for three days, in of 346 cases, the price rose further within the following month. The odds of a continued upward trend are .

KLAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KLAC as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for KLAC turned negative on July 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

KLAC moved below its 50-day moving average on July 17, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for KLAC crossed bearishly below the 50-day moving average on July 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KLAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for KLAC entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KLAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: KLAC's P/B Ratio (39.683) is very high in comparison to the industry average of (8.253). P/E Ratio (52.792) is within average values for comparable stocks, (173.765). Projected Growth (PEG Ratio) (1.847) is also within normal values, averaging (1.534). Dividend Yield (0.004) settles around the average of (0.006) among similar stocks. P/S Ratio (18.762) is also within normal values, averaging (35.325).

Notable companies

The most notable companies in this group are Applied Materials (NASDAQ:AMAT), Lam Research Corp (NASDAQ:LRCX), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 64.45B. The market cap for tickers in the group ranges from 555.66K to 663.18B. ASML holds the highest valuation in this group at 663.18B. The lowest valued company is AVSR at 555.66K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 8%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 46%. AXTI experienced the highest price growth at 60%, while SMTK experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was -47%. For the same stocks of the Industry, the average monthly volume growth was -41% and the average quarterly volume growth was -68%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 34
Price Growth Rating: 43
SMR Rating: 74
Profit Risk Rating: 64
Seasonality Score: -23 (-100 ... +100)
View a ticker or compare two or three
KLAC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of process control and yield management solutions for the semiconductor and related nanoelectronics industries

Industry ElectronicProductionEquipment

Profile
Details
Industry
Electronic Production Equipment
Address
One Technology Drive
Phone
+1 408 875-3000
Employees
15200
Web
https://www.kla.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.